Placeholder

Privyet! Russia: Growth and Opportunity

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

With its promise of expansion, its population of around 140 million potential customers, and a pool of highly qualified staff, Russia has long been recognized as an important market for pharmaceutical companies.
The pharma market in Russia has shown stable annual growth of 13% to 20% for several years, and growth forecasts for 2011 range from 8% to 15%.
Many pharmaceutical companies started their operations in Russia in the early 1990s, and today, most have offices in Russia with hundreds of full-time employees, says Pavel Tverdokhleb, senior director, clinical research, at PharmaNet.
Pharmaceutical companies have been expanding their presence in Russia in recent months, and more companies are expected to establish a local presence in response to efforts by the Russian government to bolster the domestic sector and cut dependence on imports through the 2020 Healthcare…

Sidebars:
Russia: Healthcare System Fast Facts (2005 — 2009)
International Clinical Trials in Russia 2005-2009
Paying for Medicines

Experts
Natalia Aksenova
. Managing Director, Partner, Sudler & Hennessey/AG Loyalty, The S&H Group is a global healthcare marketing and communications organization with offices around the world. (S&H entered a partnership with AG Loyalty Moscow in 2009 expanding its reach into the Russian Federation.) For more information, visit sudler.com.
Angelico Carta, M.D. President, Worldwide Clinical Trials Global, a privately held global CRO with full-service clinical development capabilities. For more information, visit wwctrials.com.
Jostein Davidsen. Senior VP and President, Nycomed Russia-CIS, Nycomed, a privately owned, global pharmaceutical company with a presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia, and Latin America. For more ­information, visit nycomed.com.
Dominika Grzywinska. Consulting Analyst, CEE Healthcare, Frost & Sullivan, a provider of consulting services. For more information, visit frost.com.
Valentin Janz. Coordinator of Boehringer Ingelheim’s initiatives in emerging markets (Russia and India), Boehringer Ingelheim is a research-driven group of companies ­dedicated to developing, manufacturing, and ­marketing ­pharmaceuticals that improve health and quality of life. For more information, visit boehringer-ingelheim.com.
Ronny Schnel. Executive Director, ­Business Development and Client Services, Criterium Inc., a global, full-service, and technology-driven CRO. For more ­information, visit criteriumusa.com.
Pavel Tverdokhleb. Senior Director, Clinical Research, PharmaNet, a global drug development services company that ­provides capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence ­services, regulatory, staffing, and therapeutic solutions. For more information, visit pharmanet.com.
Alexandra Zaichenko. Director, ­Business Development, Global Clinical ­Trials, a full-service CRO, experienced in clinical development in Eastern Europe and Russia. For more information, visit gctrials.com.
Tatjana Zwereva, M.D., Ph.D. Country Manager, i3 Russia, i3 is a full-spectrum CRO with functional and therapeutic ­expertise to help biopharmaceutical ­companies across the globe gain insights that lead to better patient care. For more information, visit i3global.com.

FEEDBACK